Shijiazhuang Pharmaceutical Group Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Guangzhou Mingkang Bioengineering Co., Ltd. was established in 2000 in Guangzhou Economic and Technological Development Zone. It is a high-tech biotechnology company dedicated to the research, development, and production of recombinant protein drugs using biotechnology, with a registered capital of 140 million yuan. Located in the biological park on Jinfengyuan Road, Science City, Guangzhou, it covers an area of 35,837 square meters.
The company's management team has extensive experience in biopharmaceutical R&D and production, quality control, engineering management, financial operations, and human resource management. The technical team has rich experience in animal cell culture technology and protein separation technology.
The company has independently developed and successfully industrialized a single-dose thrombolytic drug for acute myocardial infarction treatment—Tenecteplase for Injection (Mingfule), which has been approved for market.
With the mission of "Remembering social responsibility and caring for human health," the company holds a lofty purpose, attaches importance to drug quality, and focuses on technological innovation, aiming to give back to society with advanced technology and high-quality products.